Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$124.71 USD

124.71
2,562,050

+1.24 (1.00%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $125.01 +0.30 (0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Value Investors Buy BioNTech (BNTX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How Much Upside is Left in BioNTech SE Sponsored ADR (BNTX)? Wall Street Analysts Think 40.69%

by Zacks Equity Research

The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 40.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug

by Zacks Equity Research

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

New Strong Buy Stocks for July 11th

by Zacks Equity Research

BLBD, BNTX, EC, TIMB and HIVE have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2023.

Novavax's (NVAX) COVID Jab Gets Full Approval in Europe

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine, Nuvaxovid, gets full marketing authorization for COVID patients in Europe.

Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Implied Volatility Surging for BioNTech (BNTX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

by Zacks Equity Research

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody

by Zacks Equity Research

BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

Are Options Traders Betting on a Big Move in BioNTech (BNTX) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Will Pfizer (PFE) Beat Expectations This Earnings Season?

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.

Sundeep Ganoria headshot

FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations

by Sundeep Ganoria

To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $124.57, marking a +1.63% move from the previous day.

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Wynn Resorts and BioNTech have been highlighted as Zacks Bull and Bear of the Day.

Andrew Rocco headshot

Bear of the Day: BioNTech (BNTX)

by Andrew Rocco

BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.

Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $132.08, marking a +1.88% move from the previous day.

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $129.77, moving +1.82% from the previous trading session.

BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BioNTech's (BNTX) fourth-quarter COVID-19 vaccine sales are likely to have declined with the pandemic largely in control. Updates on the company's booster dose authorization status and pipeline will be in focus.

BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) closed at $131.54 in the latest trading session, marking a +0.59% move from the prior day.